Results 301 to 310 of about 624,360 (317)

Adaptations in control of blood flow with training: splanchnic and renal blood flows

, 1998
R. M. McAllister
openalex   +1 more source

Expert Perspectives on a Clinical Challenge: Hematologic Malignancies and Vasculitis

Arthritis &Rheumatology, Accepted Article.
Systemic vasculitis describes a collection of rare diseases each caused by inflammation of blood vessel walls that can cause severe systemic complications [[3, 4]](#ref‐0003). The pattern of vascular inflammation and resultant damage is frequently variable and may be mimicked, or directly triggered, by infection or malignancy.
Michelle L. Robinette, Hetty E. Carraway
wiley   +1 more source

Aberrant glycosylation of IgG in children with active lupus nephritis alters podocyte metabolism and causes podocyte injury

Arthritis &Rheumatology, Accepted Article.
Background Podocytes are integral to the maintenance of the glomerular filtration barrier. Their injury results in proteinuria and disease progression in lupus nephritis (LN). Aberrant IgG glycosylation drives podocyte injury in LN and leads to cytoskeletal rearrangement, motility changes and decreased nephrin production.
Rhea Bhargava, Rohit Upadhyay, Cong Zhao, Prasad Katakam, Scott Wenderfer, Jing Chen, Hua He, Richard Cummings, Maria G. Tsokos, George C. Tsokos   +9 more
wiley   +1 more source

Correction to: Cyclooxygenase-2 Selectively Controls Renal Blood Flow Through a Novel PPARβ/δ-Dependent Vasodilator Pathway. [PDF]

Hypertension, 2018
europepmc   +1 more source

Differences in dynamics of specific anti‐nuclear antibodies and their susceptibility to B cell targeting treatment in Systemic Lupus Erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective The presence of anti‐nuclear antibodies (ANAs) is characteristic for systemic lupus erythematosus (SLE). Antibody dynamics over time are thought to reflect the cellular source of ANAs and their therapeutic targetability. Anti‐dsDNA is the most prevalent and well‐studied of all ANAs, and fluctuations in anti‐dsDNA serum levels are associated ...
Hugo J. van Dooren, Mieke van Schaik, Annemarie L. Dorjée, Eline J. Arends, Meggan Mackay, Cooney Laura, David A. Fox, David Wofsy, Dawn Smilek, Cynthia Aranow, Maria Dall'Era, Tom W.J. Huizinga, Cees van Kooten, René E.M. Toes, Betty Diamond, Y.K. Onno Teng, Jolien Suurmond   +16 more
wiley   +1 more source

Mucosal‐associated invariant T cells in rheumatic diseases.

Arthritis &Rheumatology, Accepted Article.
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor (TCR) and restriction by the MHC class I‐related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines. Upon activation, MAIT cells rapidly produce pro‐inflammatory cytokines,
Manon Lesturgie‐Talarek, Virginie Gonzalez, Lucie Beaudoin, Noémie Sénot, Corinne Miceli‐Richard, Yannick Allanore, Agnès Lehuen, Jerôme Avouac   +7 more
wiley   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Arthritis &Rheumatology, Accepted Article.
Summary Castleman disease (CD) is a major diagnostic challenge for Rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y.C. Chen, Lu Zhang, David C. Fajgenbaum   +2 more
wiley   +1 more source

Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of study was to generate quantitative data on the abundance of drug‐metabolizing enzymes and transporters (DMETs) in inflamed and non‐inflamed Crohn's disease (CD) ileum and colon, for incorporation into physiologically based pharmacokinetic (PBPK) models, enabling prediction of oral drugs' pharmacokinetics (PK) perturbation in CD patients.
Sarah Alrubia, Brahim Achour, Zubida M. Al‐Majdoub, Amin Rostami‐Hodjegan, Jill Barber   +4 more
wiley   +1 more source

Anticoagulation intensity and outcomes among southeast‐Asians with moderate‐to‐severe mitral valve stenosis

British Journal of Clinical Pharmacology, EarlyView.
Objective To determine the optimal anticoagulation intensity of warfarin in a South‐East Asian population with moderate‐to‐severe rheumatic mitral stenosis. Methods A multicentre, retrospective study examined patients with rheumatic mitral stenosis who had not undergone valve replacement or repair and required long‐term warfarin therapy at two ...
Punyawee Puchsaka, Wipharak Rattanavipanon, Sararat Phetroong, Rudeekorn Ue‐sethasakdhi, Suparat Wattanasombat, Wattana Wongtheptien, Surakit Nathisuwan   +6 more
wiley   +1 more source

Pharmacokinetics of betamethasone in pre‐eclampsia: An in vivo and ex vivo study

British Journal of Clinical Pharmacology, EarlyView.
Aims To enhance understanding of betamethasone and its metabolites' pharmacokinetics in pregnancy, specifically early‐onset pre‐eclampsia, through a population pharmacokinetic model. Additionally, to investigate the placental metabolism and transfer of betamethasone and its main metabolites.
Sam Schoenmakers, Letao Li, Anna C. M. Kluivers, Michelle Broekhuizen, Madhavi S. Harhangi, A. H. Jan Danser, Irwin Reiss, Karel Allegaert, Sjoerd A. A. van den Berg, Bertrand D. van Zelst, Ron H. N. van Schaik, Philip L. J. DeKoninck, Emma Ronde, Sebastiaan D. T. Sassen, Sinno H. P. Simons, Birgit C. P. Koch   +15 more
wiley   +1 more source